Charcot--Marie-Tooth disease type 1A (CMT1A) is a hereditary peripheral neuropathy characterized by progressive demyelination and distal muscle weakness. Abnormal expression of peripheral myelin protein 22 (PMP22) has been linked to CMT1A and is modeled by Trembler J (TrJ) mice, which carry the same leucine to proline substitution in PMP22 as affected pedigrees. Pharmacologic modulation of autophagy by rapamycin in neuronSchwann cell explant cultures from neuropathic mice reduced PMP22 aggregate formation and improved myelination. Here we asked whether rapamycin administration by food supplementation, or intraperitoneal injection, could alleviate the neuropathic phenotype of affected mice and improve neuromuscular performance. Cohorts of male and female wild type (Wt) and TrJ mice were assigned to placebo or rapamycin treatment starting at 2 or 4 months of age and tested monthly on the rotarod. While neither long-term feeding (8 or 10 months) on rapamycin-enriched diet, or short-term injection (2 months) of rapamycin improved locomotor performance of the neuropathic mice, both regimen benefited peripheral nerve myelination. Together, these results indicate that while treatment with rapamycin benefits the myelination capacity of neuropathic Schwann cells, this intervention does not improve neuromuscular function. The observed outcome might be the result of the differential response of nerve and skeletal muscle tissue to rapamycin.
Introduction
Charcot-Marie-Tooth (CMT) neuropathies comprise a heterogeneous group of disorders that affect approximately 1:2500 (Skre, 1974) . The most common form is CMT type 1A, which is typically linked with duplication of the peripheral myelin protein 22 (PMP22) gene, though point mutations in PMP22 have also been identified (Young and Suter, 2003) . The Trembler J (TrJ) mouse harbors the same point mutation in PMP22 that is found in a cohort of CMT1A patients (Suter et al., 1992) . Nerves of affected mice show demyelination, degenerating axonal profiles, increases in extracellular tissue deposits and Schwann cell hyperproliferation (Notterpek et al., 1997) . With age and disease progression, affected mice develop neuromuscular deficits, which are paralleled by degenerative changes at the neuromuscular junction (NMJ) and distal muscle atrophy (Nicks et al., 2013) .
PMP22 is a tetraspan constituent of the Schwann cell membrane that has a high propensity to aggregate (Pareek et al., 1997) . When the amount of newly-synthesized PMP22 destined for degradation exceeds the capacity of the proteasome, misfolded PMP22 accumulates in cytosolic aggregates (Fortun et al., 2003 (Fortun et al., , 2007 . Similar cellular pathology has been observed in nerve samples from PMP22-linked neuropathic patients (Hanemann et al., 2000; Nishimura et al., 1996) , as well as animal models (Fortun et al., 2003 (Fortun et al., , 2006 . Approaches to prevent the accumulation of misfolded proteins within cells include enhancement of the autophagy-lysosomal pathway (Kubota et al., 1999) either with small compounds, or through calorie restriction (Mattson, 2008) . Identification of a safe and effective calorie restriction mimetic for the treatment and prevention of age-related neural disorders is of great interest (Ingram et al., 2006) . Among molecules tested, rapamycin has yielded promising results through the activation of 
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